Brought to you by 
MacroGenics grants Servier an option to license MGA271 for cancer; deal ends
05 Oct 2021
Executive Summary
MacroGenics Inc. (therapeutics for autoimmune and infectious diseases and cancer) has granted Servier SA an option to license exclusive worldwide rights (excluding the US, Canada, Mexico, Japan, Korea, and India) to MGA271, in Phase I for solid tumors.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
MacroGenics grants Servier an option to license MGA271 for cancer; deal ends
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice